Company intelligence / Profile preview

NanoCor Therapeutics

Chapel Hill, North Carolina, United Statesnanocorthx.com ↗

Ownership: Private
Development stage: Other

Overview

Pre-clinical studies showed up to 25% improvement in heart function in porcine models; FDA accepted IND for Phase 1 trial for Carfostin, targeting advanced chronic heart failure, but no published results of human studies

Therapeutic areas: Cardiovascular
Modalities: Gene therapyBiologicAdeno-associated virus vector therapy
Industry: Biotech

Partnerships

Collaborations with academic centers notably Icahn School of Medicine at Mount Sinai for preclinical and planned clinical studies

Beyond the preview

Go deeper on NanoCor Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NanoCor Therapeutics.